▲ +66.10% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Instil Bio in the last 3 months. The average price target is $29.50, with a high forecast of $32.00 and a low forecast of $23.00. The average price target represents a 66.10% upside from the last price of $17.76.
The current consensus among 5 investment analysts is to buy stock in Instil Bio.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.